Ontology highlight
ABSTRACT:
SUBMITTER: Rubinstein E
PROVIDER: S-EPMC3060890 | biostudies-literature | 2011 Jan
REPOSITORIES: biostudies-literature
Rubinstein Ethan E Lalani Tahaniyat T Corey G Ralph GR Kanafani Zeina A ZA Nannini Esteban C EC Rocha Marcelo G MG Rahav Galia G Niederman Michael S MS Kollef Marin H MH Shorr Andrew F AF Lee Patrick C PC Lentnek Arnold L AL Luna Carlos M CM Fagon Jean-Yves JY Torres Antoni A Kitt Michael M MM Genter Fredric C FC Barriere Steven L SL Friedland H David HD Stryjewski Martin E ME
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110101 1
<h4>Background</h4>Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens.<h4>Methods</h4>Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired pneumonia (HAP) due to gram-positive pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA). Patients were randomized 1:1 to telavancin (10 mg/kg every 24 h) or vancomycin (1 g every 12 h) for 7-21 days. The primary end point was clinical re ...[more]